Shao-Lee Lin, Acelyrin CEO
April 13, 2023 06:19 PM EDTUpdated April 14, 07:26 AM
Financing
Startups

Ace­lyrin files to go pub­lic in rare sign of biotech IPO

Kyle LaHucik

Senior Reporter

Cal­i­for­nia biotech Ace­lyrin has filed to go pub­lic, a rare at­tempt to ac­cess the stock mar­kets af­ter a year of stock …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Roche could re­think $50B US ex­pan­sion plan if new poli­cies 'har­m' op­er­a­tions

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

PBM over­haul and drug price ne­go­ti­a­tions make the cut in Re­pub­li­can­s' tax bill

A service from the Financial Times